Objective: Assessing the effects of maternal anxiety on the markers and results of quadruple screening and on maternal anxiety after receiving positive results. Methods: This prospective cohort study evaluated 1,595 pregnant women referred for prenatal visits. Maternal state/trait anxiety levels were measured, then quadruple screening was performed by measuring serum α-fetoprotein (AFP), β-human chorionic gonadotropin, inhibin A, and unconjugated estriol (UE3). After receiving the results, the state/trait anxiety was remeasured. Amniocentesis was performed for screening-positive mothers. Results: High prescreening maternal anxiety was associated with lower rates of elevated AFP (OR, 0.27; 95% CI, 0.1-0.74) and elevated inhibin A (OR, 0.38; 95% CI, 0.15-0.98). High maternal anxiety was associated with higher rates of decreased UE3 (OR, 1.8; 95% CI, 1.06-3.08). There were no significant associations between prescreening maternal anxiety and the final screening or amniocentesis results. Among the screening-positive mothers, those who had high state/trait anxiety before screening had higher anxiety scores after receiving positive results compared to those with low prescreening anxiety levels (52.9 ± 10.8 vs. 43.7 ± 10.3). Conclusion: High prescreening maternal anxiety is associated with lower rates of elevated AFP and inhibin A and higher rates of decreased UE3. However, maternal anxiety does not affect the final screening or amniocentesis result. High maternal state/trait anxiety before screening is associated with significantly higher maternal anxiety after the receipt of positive results.

Keywords:
Anxiety, Estriol, Fetoprotein, Human chorionic gonadotropin, Quadruple screening, Inhibin, Pregnancy, Stress
1.
Wald NJ, Kennard A, Hackshaw A, McGuire A: Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246.
2.
Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al: First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-2011.
3.
Benn PA, Ying J, Beazoglou T, Egan JF: Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results. Prenat Diagn 2001;21:46-51.
4.
Jorgensen FS: User acceptability of an alpha-fetoprotein screening programme. Dan Med Bull 1995;42:100-105.
5.
Ding XX, Wu YL, Xu SJ, Zho RP, Jia XM, Zhang SF, Huang K, Zhu P, Hao JH, Tao FB: Maternal anxiety during pregnancy and adverse birth outcomes: a systematic review and meta-analysis of prospective cohort studies. J Affect Disord 2014;159:103-110.
6.
Maltau JM, Eielsen OV, Stokke KT: Effect of stress during labor on the concentration of cortisol and estriol in maternal plasma. Am J Obstet Gynecol 1979;134:681-684.
7.
Keshavarzi F, Farnia V, Yazdchi K, Najafi F, Brand S, Bajoghli H, Nankali A, Salmanzadeh H: Effect of maternal anxiety on maternal serum and fetal cord blood cortisol. Asia Pac Psychiatry 2014;6:435-439.
8.
Patrick J, Challis J, Natale R, Richardson B: Circadian rhythms in maternal plasma cortisol, estrone, estradiol, and estriol at 34 to 35 weeks' gestation. Am J Obstet Gynecol 1979;135:791-798.
9.
Chou JY, Mano T, Feldman M: Inhibition of synthesis of alpha-fetoprotein by glucocorticoids in cultured hepatoma cells. J Cell Biol 1982;93:314-317.
10.
Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V, Friese K: Immunohistochemical expression of inhibin-alpha in human endometrium and the in vitro secretion of inhibin, estradiol and cortisol in cultured human endometrial glandular cells. Arch Gynecol Obstet 2003;268:142-150.
11.
Spielberger CD, Gorssuch RL, Lushene PR, Vagg PR, Jacobs GA: Manual for the State-Trait Anxiety Inventory. Palo Alto, Consulting Psychologists Press, 1983.
12.
Holmes TH, Rahe RH: The Social Readjustment Rating Scale. J Psychosom Res 1967;11:213-218.
13.
Glover V, Bergman K, Sarkar P, O'Connor TG: Association between maternal and amniotic fluid cortisol is moderated by maternal anxiety. Psychoneuroendocrinology 2009;34:430-435.
14.
O'Donnell KJ, Bugge Jensen A, Freeman L, Khalife N, O'Connor T, Glover V: Maternal prenatal anxiety and downregulation of placental 11β-HSD2. Psychoneuroendocrinology 2012;37:818-826.
15.
Kane HS, Dunkel Schetter C, Glynn LM, Hobel CJ, Sandman CA: Pregnancy anxiety and prenatal cortisol trajectories. Biol Psychol 2014;100:13-19.
16.
Gitlin D, Boesman M: Serum α-fetoprotein synthesis in the human and rat fetus and its inhibition in the rat. Pediatr Res 1967;1:216-217.
17.
Wood CE: Negative-feedback inhibition of fetal ACTH secretion by maternal cortisol. Am J Physiol 1987;252:R743-R748.
18.
Vanttinen T, Kuulasmaa T, Liu J, Voutilainen R: Expression of activin/inhibin receptor and binding protein genes and regulation of activin/inhibin peptide secretion in human adrenocortical cells. J Clin Endocrinol Metab 2002;87:4257-4263.
19.
Spencer SJ, Rabinovici J, Mesiano S, Goldsmith PC, Jaffe RB: Activin and inhibin in the human adrenal gland. Regulation and differential effects in fetal and adult cells. J Clin Invest 1992;90:142-149.
20.
Maltau JM, Stokke KT, Moe N: Effects of betamethasone on plasma levels of estriol, cortisol and HCS in late pregnancy. Acta Obstet Gynecol Scand 1979;58:235-238.
21.
Zachmann M, Girard J, Duc G, Illig R, Prader A: Low urinary estriol during pregnancy caused by isolated fetal ACTH-deficiency. Acta Paediatr Scand Suppl 1979;277:26-31.
22.
Smedler AC, Bremme K: Pregnant women participating in screening must be helped with anxiety generated by alarming information (in Swedish). Lakartidningen 1992;89:652-653.
23.
Field T, Diego M, Delgado J, Medina L: Yoga and social support reduce prenatal depression, anxiety and cortisol. J Bodyw Mov Ther 2013;17:397-403.
24.
Keenan KL, Basso D, Goldkrand J, Butler WJ: Low level of maternal serum alpha-fetoprotein: its associated anxiety and the effects of genetic counseling. Am J Obstet Gynecol 1991;164:54-56.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.